Home > News Shots > India

By Saradha | Sep 04, 2020 09:25 PM

A research paper published in The Lancet Friday confirmed that patients who were involved in the early tests of a Russian coronavirus vaccine have developed antibodies with “no serious adverse events”. 

russian vaccine sputnikv passes early trial test says Lancet study

Russia had launched its vaccine named Sputnik V. Since the vaccine received approval within two months of trials, it raised concerns among many western scientists. 

Russian researchers who published their research in Lancet study had reported on two small trials. Each group had around 38 healthy adults who were between the age groups of 18 to 60. They were prescribed a two- part dosage. 

Every individual had to take the second dosage, 21 days after the first dosage was administered to them. The report states that the vaccine is safe, it was well tolerated and does not cause adverse impact among healthy adult volunteers. 

Researchers revealed that larger and longer trials are the need of the hour to determine if the vaccine is safe in long term. 

According to the report, “76 participants of these trials would be monitored up to 180 days, adding that a more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers from different age and risk groups.”

Naor Bar-Zeev of Johns Hopkins Bloomberg School of Public Health, who was not involved in the study expressed that the study was effective but however, it was small. The study needs to be held among people who are particularly vulnerable. 

"Showing safety will be crucial with Covid-19 vaccines, not only for vaccine acceptance but also for trust in vaccination broadly," he said. 

"Since vaccines are given to healthy people and, during the COVID-19 pandemic, potentially to everyone after approval following phase 3 trials, safety is paramount,” he added.

அரசியல், விளையாட்டு, நாட்டுநடப்பு, குற்ற சம்பவங்கள், வர்த்தகம், தொழில்நுட்பம், சினிமா, வாழ்க்கை முறை என பலதரப்பட்ட சுவாரஸ்யமான செய்திகளை தமிழில் படிக்க இங்கு கிளிக் செய்யவும்      



This page contains news relating to various facts and events. The views are generally about current affiars and general topics in diversified areas such as political, international, national, and regional issues, sports, health, travel, lifestyle, technology and business. People having similar interets on the above topics will find this page useful. Russian vaccine sputnikv passes early trial test says Lancet study | India News.